NeuBase Therapeutics Inc
F:O7PA
NeuBase Therapeutics Inc
Other Current Assets
NeuBase Therapeutics Inc
Other Current Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Current Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
N
|
NeuBase Therapeutics Inc
F:O7PA
|
Other Current Assets
$780k
|
CAGR 3-Years
-2%
|
CAGR 5-Years
26%
|
CAGR 10-Years
32%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Other Current Assets
$5.2B
|
CAGR 3-Years
4%
|
CAGR 5-Years
10%
|
CAGR 10-Years
9%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Other Current Assets
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Other Current Assets
$4.1B
|
CAGR 3-Years
20%
|
CAGR 5-Years
15%
|
CAGR 10-Years
9%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Other Current Assets
$853.3m
|
CAGR 3-Years
16%
|
CAGR 5-Years
23%
|
CAGR 10-Years
21%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Other Current Assets
$1.2B
|
CAGR 3-Years
43%
|
CAGR 5-Years
50%
|
CAGR 10-Years
22%
|
|
NeuBase Therapeutics Inc
Glance View
NeuBase Therapeutics, Inc. is a biotechnology company, which engages in the development of drugs for patients with genetic neurological disorders. The company is headquartered in Pittsburgh, Pennsylvania and currently employs 33 full-time employees. The firm is focused on developing therapies to treat rare genetic diseases and cancers caused by mutant genes. The Company’s peptide-nucleic acid antisense oligonucleotide (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders. Its programs include NT0100, a PATrOL-enabled therapeutic program for systemic administration to target the mutant expansion in the HD messenger ribonucleic acid (mRNA) and NT0200, a PATrOL-enabled therapeutic program for systemic administration to target the mutant expansion in the myotonic dystrophy type one disease mRNA.
See Also
What is NeuBase Therapeutics Inc's Other Current Assets?
Other Current Assets
780k
USD
Based on the financial report for Sep 30, 2023, NeuBase Therapeutics Inc's Other Current Assets amounts to 780k USD.
What is NeuBase Therapeutics Inc's Other Current Assets growth rate?
Other Current Assets CAGR 10Y
32%
Over the last year, the Other Current Assets growth was -48%. The average annual Other Current Assets growth rates for NeuBase Therapeutics Inc have been -2% over the past three years , 26% over the past five years , and 32% over the past ten years .
